Ubrelvy, also known by its generic name ubrogepant, was approved by the U.S. Food and Drug Administration (FDA) on December 23, 2019 [1]. This approval marked the first in a new class of oral medications for acute migraine treatment [2].
When does Ubrelvy's patent expire?
DrugPatentWatch.com provides detailed patent information for Ubrelvy. According to their data, the earliest patent for Ubrelvy was filed in 2014 [3]. The latest patent expiration date for Ubrelvy is projected to be in 2038 [3].
What are the active ingredients in Ubrelvy?
Ubrelvy's active ingredient is ubrogepant [1]. Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [2].
How does Ubrelvy work for migraine?
Ubrelvy works by blocking the activity of CGRP, a molecule that plays a role in migraine pain and inflammation [2]. By inhibiting CGRP, the drug helps to reduce migraine symptoms [2].
What is Ubrelvy used to treat?
Ubrelvy is indicated for the acute treatment of migraine with or without aura in adults [1]. It is taken as needed to relieve migraine attacks that are already in progress [2].
Can Ubrelvy be used to prevent migraines?
Ubrelvy is not indicated for migraine prevention. It is specifically approved for the acute treatment of existing migraine attacks [1].